STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8
Clinical trials for STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets tough cancers using biomarker clues
Disease control Recruiting nowThis study tests two drugs, cabozantinib and nivolumab, in 150 people with advanced melanoma or head and neck cancer that hasn't responded to prior immunotherapy. The goal is to see if the combination shrinks tumors and how quickly doctors can use tumor biomarkers to sort patient…
Matched conditions: STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:28 UTC
-
New hope for Hard-to-Treat head and neck cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer. The cancer has either come back or spread and no longer responds to platinum chemotherapy. About 158 adults will be randomly assigned to …
Matched conditions: STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has returned or spread. The goal is to find the safest dose and see if the vaccine helps the immune system …
Matched conditions: STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding the cholesterol-lowering drug lovastatin to the immunotherapy pembrolizumab can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS≥1) will receive both drugs.…
Matched conditions: STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Can blood tests predict who will do their swallowing exercises?
Knowledge-focused Recruiting nowThis study looks at why people with head and neck cancer do or don't follow swallowing exercises after radiation. Researchers will use blood tests and questionnaires to see if immune system proteins or feelings about the illness affect exercise habits. The goal is to learn what h…
Matched conditions: STAGE IV HYPOPHARYNGEAL CARCINOMA AJCC V8
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated May 12, 2026 13:43 UTC